Skip to search formSkip to main contentSkip to account menu

ALK5 Inhibitor TEW-7197

Known as: TEW-7197, TEW7197, TGFBR1 Inhibitor TEW-7197 
An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AB083. TEW-7197, a novel orally bioavailable activin receptor-like kinase 5 inhibitor, promotes regression of fibrotic plaque in a rat model of Peyronie’s disease
Background To examine therapeutic effect of TEW-7197, a novel small molecule inhibitor of activin receptor-like kinase 5 (ALK5… 
2017
2017
Abstract 2647: TGF-β type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib
Background: Multiple myeloma (MM) is an incurable cancer of plasma cells. MM thrives in the bone marrow tumor microenvironment… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)